Show how much they raised and what is the stage?
The same 20 Stanford dy/dx startups from the previous report, now each with a public cumulative funding figure and a named equity stage. Amounts are in US dollars, per the single selected source shown for each company; latest rounds run from mid-2022 to April 2026.
Think Bioscience alone accounts for roughly a fifth of the cohort's capital, with a $55M Series A closed in January 2026 — pitchbook.com
The top three — Think Bioscience, k-ID and Notch — together hold $174.2M, nearly half of everything raised — prnewswire.com
Every Series A company has raised more than every Seed company: the stage line falls cleanly between JITX at $12.9M and BioLoomics at $10.4M — pitchbook.com
The freshest money is at the bottom of the table: shapes inc closed its $8M seed in April 2026, the newest round in the cohort — techcrunch.com
| # | Company | Total raised | Stage | Latest round | Date | Source |
|---|
Totals are public figures and estimates. They can differ slightly among databases because of undisclosed tranches, currency conversion, and debt or grant financing that some trackers include. This report uses the single selected source shown beside each company, and treats "stage" as the most advanced publicly completed named equity round.
Follow-up to the prior dy/dx valuation-disclosure report. 20 rows, one per company, ranked by cumulative funding in USD; latest round dates 2022–2026. Each figure comes from the linked source; stage is the latest completed named equity round. Nothing was cut for space.